Pharmacologically Induced Weight Loss is Associated with Distinct Gut Microbiome Changes in Obese Rats

Overview

Journal BMC Microbiol

Publisher Biomed Central

Specialty Microbiology

Date 2022 Apr 8

PMID 35392807

Authors

Silvia Raineri

Julia A Sherriff

Kevin S J Thompson

Huw Jones

Paul T Pfluger

Nicholas E Ilott

Jane Mellor

Affiliations

Soon will be listed here.

Abstract

Background: Obesity, metabolic disease and some psychiatric conditions are associated with changes to relative abundance of bacterial species and specific genes in the faecal microbiome. Little is known about the impact of pharmacologically induced weight loss on distinct microbiome species and their respective gene programs in obese individuals.

Methodology: Using shotgun metagenomics, the composition of the microbiome was obtained for two cohorts of obese female Wistar rats (n = 10-12, total of 82) maintained on a high fat diet before and after a 42-day treatment with a panel of four investigatory or approved anti-obesity drugs (tacrolimus/FK506, bupropion, naltrexone and sibutramine), alone or in combination.

Results: Only sibutramine treatment induced consistent weight loss and improved glycaemic control in the obese rats. Weight loss was associated with reduced food intake and changes to the faecal microbiome in multiple microbial taxa, genes, and pathways. These include increased β-diversity, increased relative abundance of multiple Bacteroides species, increased Bacteroides/Firmicutes ratio and changes to abundance of genes and species associated with obesity-induced inflammation, particularly those encoding components of the flagellum and its assembly.

Conclusions: Sibutramine-induced weight loss in obese rats is associated with improved metabolic health, and changes to the faecal microbiome consistent with a reduction in obesity-induced bacterially-driven inflammation.

Citing Articles

The interplay of gut microbiota, obesity, and depression: insights and interventions.

Halabitska I, Petakh P, Kamyshna I, Oksenych V, Kainov D, Kamyshnyi O Cell Mol Life Sci. 2024; 81(1):443.

PMID: 39476179 PMC: 11525354. DOI: 10.1007/s00018-024-05476-w.

A new perspective in intestinal microecology: lifting the veil of exercise regulation of cardiometabolic diseases.

Gao C, Wei J, Lu C, Wang L, Dong D, Sun M Gut Microbes. 2024; 16(1):2404141.

PMID: 39305272 PMC: 11418258. DOI: 10.1080/19490976.2024.2404141.

Pharmacomicrobiomics of Classical Immunosuppressant Drugs: A Systematic Review.

Manes A, Di Renzo T, Dodani L, Reale A, Gautiero C, Di Lauro M Biomedicines. 2023; 11(9).

PMID: 37761003 PMC: 10526314. DOI: 10.3390/biomedicines11092562.

Impact of the herbal medicine, stapf on gut microbiota and body weight in a diet-induced obesity model.

Song E, Shin N, Jeon S, Nam Y, Kim H Front Pharmacol. 2022; 13:1042833.

PMID: 36457710 PMC: 9706310. DOI: 10.3389/fphar.2022.1042833.

From Gut Microbiota through Low-Grade Inflammation to Obesity: Key Players and Potential Targets.

Vetrani C, Di Nisio A, Paschou S, Barrea L, Muscogiuri G, Graziadio C Nutrients. 2022; 14(10).

PMID: 35631244 PMC: 9145366. DOI: 10.3390/nu14102103.

References

Bornfeldt K, Tabas I . Insulin resistance, hyperglycemia, and atherosclerosis. Cell Metab. 2011; 14(5):575-85. PMC: 3217209. DOI: 10.1016/j.cmet.2011.07.015. View

Turnbaugh P, Ley R, Mahowald M, Magrini V, Mardis E, Gordon J . An obesity-associated gut microbiome with increased capacity for energy harvest. Nature. 2006; 444(7122):1027-31. DOI: 10.1038/nature05414. View

McMurdie P, Holmes S . phyloseq: an R package for reproducible interactive analysis and graphics of microbiome census data. PLoS One. 2013; 8(4):e61217. PMC: 3632530. DOI: 10.1371/journal.pone.0061217. View

Cryan J, Dinan T . Mind-altering microorganisms: the impact of the gut microbiota on brain and behaviour. Nat Rev Neurosci. 2012; 13(10):701-12. DOI: 10.1038/nrn3346. View

Liu R, Hong J, Xu X, Feng Q, Zhang D, Gu Y . Gut microbiome and serum metabolome alterations in obesity and after weight-loss intervention. Nat Med. 2017; 23(7):859-868. DOI: 10.1038/nm.4358. View

Zhang H, DiBaise J, Zuccolo A, Kudrna D, Braidotti M, Yu Y . Human gut microbiota in obesity and after gastric bypass. Proc Natl Acad Sci U S A. 2009; 106(7):2365-70. PMC: 2629490. DOI: 10.1073/pnas.0812600106. View

Takekawa N, Terahara N, Kato T, Gohara M, Mayanagi K, Hijikata A . The tetrameric MotA complex as the core of the flagellar motor stator from hyperthermophilic bacterium. Sci Rep. 2016; 6:31526. PMC: 4987623. DOI: 10.1038/srep31526. View

Pfluger P, Kabra D, Aichler M, Schriever S, Pfuhlmann K, Casquero Garcia V . Calcineurin Links Mitochondrial Elongation with Energy Metabolism. Cell Metab. 2015; 22(5):838-50. DOI: 10.1016/j.cmet.2015.08.022. View

Heymsfield S, Wadden T . Mechanisms, Pathophysiology, and Management of Obesity. N Engl J Med. 2017; 376(3):254-266. DOI: 10.1056/NEJMra1514009. View

10.

Tremaroli V, Karlsson F, Werling M, Stahlman M, Kovatcheva-Datchary P, Olbers T . Roux-en-Y Gastric Bypass and Vertical Banded Gastroplasty Induce Long-Term Changes on the Human Gut Microbiome Contributing to Fat Mass Regulation. Cell Metab. 2015; 22(2):228-38. PMC: 4537510. DOI: 10.1016/j.cmet.2015.07.009. View

11.

Hyatt D, Chen G, LoCascio P, Land M, Larimer F, Hauser L . Prodigal: prokaryotic gene recognition and translation initiation site identification. BMC Bioinformatics. 2010; 11:119. PMC: 2848648. DOI: 10.1186/1471-2105-11-119. View

12.

Lai Z, Tseng C, Ho H, Cheung C, Lin J, Chen Y . Fecal microbiota transplantation confers beneficial metabolic effects of diet and exercise on diet-induced obese mice. Sci Rep. 2018; 8(1):15625. PMC: 6199268. DOI: 10.1038/s41598-018-33893-y. View

13.

Bowe J, Franklin Z, Hauge-Evans A, King A, Persaud S, Jones P . Metabolic phenotyping guidelines: assessing glucose homeostasis in rodent models. J Endocrinol. 2014; 222(3):G13-25. DOI: 10.1530/JOE-14-0182. View

14.

Vijay-Kumar M, Aitken J, Carvalho F, Cullender T, Mwangi S, Srinivasan S . Metabolic syndrome and altered gut microbiota in mice lacking Toll-like receptor 5. Science. 2010; 328(5975):228-31. PMC: 4714868. DOI: 10.1126/science.1179721. View

15.

de Almeida A, Monte-Alegre S, Zanini M, Souza A, Etchebehere M, Gontijo J . Association between prehypertension, metabolic and inflammatory markers, decreased adiponectin and enhanced insulinemia in obese subjects. Nutr Metab (Lond). 2014; 11:25. PMC: 4070164. DOI: 10.1186/1743-7075-11-25. View

16.

Yanovski S, Yanovski J . Obesity. N Engl J Med. 2002; 346(8):591-602. DOI: 10.1056/NEJMra012586. View

17.

Greenway F, Fujioka K, Plodkowski R, Mudaliar S, Guttadauria M, Erickson J . Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2010; 376(9741):595-605. DOI: 10.1016/S0140-6736(10)60888-4. View

18.

Wikoff W, Anfora A, Liu J, Schultz P, Lesley S, Peters E . Metabolomics analysis reveals large effects of gut microflora on mammalian blood metabolites. Proc Natl Acad Sci U S A. 2009; 106(10):3698-703. PMC: 2656143. DOI: 10.1073/pnas.0812874106. View

19.

Liao Y, Smyth G, Shi W . featureCounts: an efficient general purpose program for assigning sequence reads to genomic features. Bioinformatics. 2013; 30(7):923-30. DOI: 10.1093/bioinformatics/btt656. View

20.

Vickers S, Jackson H, Cheetham S . The utility of animal models to evaluate novel anti-obesity agents. Br J Pharmacol. 2011; 164(4):1248-62. PMC: 3229760. DOI: 10.1111/j.1476-5381.2011.01245.x. View